Financial Comparison: IQVIA (NYSE:IQV) & bioAffinity Technologies (NASDAQ:BIAFW)

IQVIA (NYSE:IQV) and bioAffinity Technologies (NASDAQ:BIAFW) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Earnings & Valuation

This table compares IQVIA and bioAffinity Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$14.98 billion	2.79	$1.36 billion	$7.70	29.77
bioAffinity Technologies	$7.32 million	N/A	N/A	N/A	N/A

IQVIA has higher revenue and earnings than bioAffinity Technologies.

Analyst Recommendations

This is a summary of recent recommendations for IQVIA and bioAffinity Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0	4	11	1	2.81
bioAffinity Technologies	0	0	0	0	N/A

IQVIA presently has a consensus price target of $269.36, indicating a potential upside of 17.49%. Given IQVIA’s higher probable upside, equities research analysts plainly believe IQVIA is more favorable than bioAffinity Technologies.

Profitability

This table compares IQVIA and bioAffinity Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IQVIA	9.39%	28.59%	6.76%
bioAffinity Technologies	N/A	N/A	N/A

Institutional & Insider Ownership

89.6% of IQVIA shares are held by institutional investors. 1.6% of IQVIA shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

IQVIA beats bioAffinity Technologies on 9 of the 9 factors compared between the two stocks.

About IQVIA

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.